Print

Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference

2012-09-06

Lund, Sweden, September 6, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference held September 9-11, 2012 in New York, USA. During the presentation, an update regarding Active Biotech's development programs will be provided.

The presentation will include projects in Phase III; laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project TASQ, in co-development with Ipsen as well as ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com.

The presentation will take place on September 11, at 12:05 pm US Eastern Daylight Time/ 18:05 Central European Summer Time.

For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. An additional project in clinical development is the orally administered compound 57-57 for Systemic Sclerosis. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication 8:30 a.m. CET on September 6, 2012.


pdfActive Biotech to Present at the Rodman & Renshaw Annual Global Inv



Back